The binding constraint: a new entrant without iptacopan's orphan-pathway standing has to win a substantial-benefit finding from IQWiG directly, the fight iptacopan itself never had to have.
Iptacopan's German launch cleared the two hardest AMNOG hurdles simultaneously and by different routes. As an orphan-designated therapy, its additional benefit counted as established through EMA approval alone under SGB V §35a Absatz 1 Satz 11, so IQWiG never built a head-to-head dossier against anti-C5 therapy. The G-BA then went further on 19 December 2024, finding a substantial (beträchtlich) additional benefit specifically on quality of life, real negotiating leverage GKV-Spitzenverband can use in price talks. Crovalimab does not have the same shortcut: its dossier, submitted 12 September 2024, is under active IQWiG assessment on the standard comparator-dossier track, meaning it must win its substantial-benefit finding the hard way, against whatever comparator G-BA designates, likely iptacopan itself given its now-established position.
That sets the practical readiness bar for any PNH entrant without orphan-designation standing. Pre-launch priorities follow directly: confirm orphan designation status early, since it changes the entire AMNOG pathway; build the clinical evidence package against the G-BA's likely comparator choice (iptacopan, not just eculizumab or ravulizumab); and engage Germany's concentrated referral network, the German PNH-Register at Ulm's Institute for Clinical Transfusion Medicine and Immunogenetics and the West German Cancer Center at Essen, well before the AMNOG clock starts, since both centres feed the International PNH Registry data a benefit dossier will need to cite.
The AMNOG pathway fork — orphan-designated versus standard-track PNH entrants in Germany
| Pathway | Dossier Requirement | Precedent | Status |
|---|---|---|---|
| Orphan pathway (§35a Abs.1 S.11) | None — benefit established through EMA approval | Iptacopan — substantial (beträchtlich) QoL benefit, 19 Dec 2024 | Precedent set |
| Standard track | Full comparator dossier vs G-BA-designated comparator | Crovalimab — dossier submitted 12 Sep 2024 | Under IQWiG assessment |
Sources: G-BA Nutzenbewertungsverfahren Iptacopan (Beschluss 19.12.2024); IQWiG Dossierbewertung Iptacopan (G24-16); G-BA Crovalimab benefit dossier (submitted 12.09.2024); German PNH-Register, Ulm; West German Cancer Center, Essen; International PNH Registry.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The SGB V §35a Abs.1 S.11 orphan-pathway mechanism
- what qualifies and what doesn't
- the standard-track alternative crovalimab is using instead
Delivers
- How G-BA comparator selection works
- the practical implication of iptacopan's substantial-benefit finding for the bar a new dossier must clear
Delivers
- The Ulm and Essen referral centres
- International PNH Registry data requirements for a benefit dossier
- sequencing relative to the AMNOG submission clock
Custom brief delivered in 72 hours.
Commission this briefWhat's inside
- Orphan-pathway standing as the single variable deciding AMNOG difficulty
- Pressure-tested against iptacopan's precedent and crovalimab's pending review
- SGB V §35a Abs.1 S.11 eligibility criteria
- What a standard-track dossier requires that the orphan pathway waives
- How G-BA is likely to designate comparators given iptacopan's substantial-benefit precedent
- Building evidence to clear that bar, not just the anti-C5 baseline
- Ulm and Essen — the two-centre national network
- International PNH Registry data dependencies for a benefit dossier
- Every regulatory and pricing assumption sourced and confidence-rated
- Orphan designation confirmation
- Dossier preparation against the AMNOG submission clock
- KOL and centre engagement sequencing
- Whether the client's PNH asset qualifies for orphan-designation standing under SGB V §35a Abs.1 S.11, or must build the standard-track dossier crovalimab is pursuing
- Whether pre-launch engagement with Ulm and Essen should begin ahead of the AMNOG submission clock, given both centres' registry role
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx launch readiness assessment is built from primary regulatory sources and named referral-centre data, not secondary summaries. Findings are independently verified before inclusion.
PNH Germany Launch Readiness sources: G-BA Nutzenbewertungsverfahren for iptacopan (19 Dec 2024); IQWiG Dossierbewertung G24-16; G-BA crovalimab dossier submission record; German PNH-Register (Ulm); West German Cancer Center (Essen).
- Iptacopan's orphan-pathway waiver and substantial-benefit finding verified against the live G-BA Beschluss
- Crovalimab's dossier submission date and pending IQWiG status verified against the G-BA public record
- The two-centre referral network and registry linkage verified against institutional sources
Frequently asked questions
Commission this assessment
AXLRx PNH Launch Readiness — Germany is built for commercial and market access teams preparing a German PNH launch, evaluating AMNOG pathway options, and sequencing referral-network engagement. Custom brief in 72 hours.
Specify indication, geography, and launch timeline.
AXLRx analyst confirms pathway assumptions, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.